» Articles » PMID: 36282174

Comprehensive Machine-learning Survival Framework Develops a Consensus Model in Large-scale Multicenter Cohorts for Pancreatic Cancer

Overview
Journal Elife
Specialty Biology
Date 2022 Oct 25
PMID 36282174
Authors
Affiliations
Soon will be listed here.
Abstract

As the most aggressive tumor, the outcome of pancreatic cancer (PACA) has not improved observably over the last decade. Anatomy-based TNM staging does not exactly identify treatment-sensitive patients, and an ideal biomarker is urgently needed for precision medicine. Based on expression files of 1280 patients from 10 multicenter cohorts, we screened 32 consensus prognostic genes. Ten machine-learning algorithms were transformed into 76 combinations, of which we selected the optimal algorithm to construct an artificial intelligence-derived prognostic signature (AIDPS) according to the average C-index in the nine testing cohorts. The results of the training cohort, nine testing cohorts, Meta-Cohort, and three external validation cohorts (290 patients) consistently indicated that AIDPS could accurately predict the prognosis of PACA. After incorporating several vital clinicopathological features and 86 published signatures, AIDPS exhibited robust and dramatically superior predictive capability. Moreover, in other prevalent digestive system tumors, the nine-gene AIDPS could still accurately stratify the prognosis. Of note, our AIDPS had important clinical implications for PACA, and patients with low AIDPS owned a dismal prognosis, higher genomic alterations, and denser immune cell infiltrates as well as were more sensitive to immunotherapy. Meanwhile, the high AIDPS group possessed observably prolonged survival, and panobinostat may be a potential agent for patients with high AIDPS. Overall, our study provides an attractive tool to further guide the clinical management and individualized treatment of PACA.

Citing Articles

Development of a tertiary lymphoid structure-based prognostic model for breast cancer: integrating single-cell sequencing and machine learning to enhance patient outcomes.

Zhang X, Li L, Shi X, Zhao Y, Cai Z, Ni N Front Immunol. 2025; 16:1534928.

PMID: 40078998 PMC: 11897234. DOI: 10.3389/fimmu.2025.1534928.


Deciphering key roles of B cells in prognostication and tailored therapeutic strategies for lung adenocarcinoma: a multi-omics and machine learning approach towards predictive, preventive, and personalized treatment strategies.

Zhang J, Hu D, Fang P, Qi M, Sun G EPMA J. 2025; 16(1):127-163.

PMID: 39991096 PMC: 11842682. DOI: 10.1007/s13167-024-00390-4.


Pharmacogenomics-based subtype decoded implications for risk stratification and immunotherapy in pancreatic adenocarcinoma.

Zhou X, Ba Y, Xu N, Xu H, Zhang Y, Liu L Mol Med. 2025; 31(1):62.

PMID: 39972282 PMC: 11837470. DOI: 10.1186/s10020-024-01049-6.


Integrative machine learning model of RNA modifications predict prognosis and treatment response in patients with breast cancer.

Wang T, Wang S, Li Z, Xie J, Jia Q, Hou J Cancer Cell Int. 2025; 25(1):43.

PMID: 39948551 PMC: 11827143. DOI: 10.1186/s12935-025-03651-y.


Epigenetic profiling for prognostic stratification and personalized therapy in breast cancer.

Guo X, Feng C, Xing J, Cao Y, Liu T, Yang W Front Immunol. 2025; 15:1510829.

PMID: 39877345 PMC: 11772270. DOI: 10.3389/fimmu.2024.1510829.


References
1.
Chen S, He Z, Peng T, Zhou F, Wang G, Qian K . PRR11 promotes ccRCC tumorigenesis by regulating E2F1 stability. JCI Insight. 2021; 6(19). PMC: 8525590. DOI: 10.1172/jci.insight.145172. View

2.
Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope F . Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discov. 2020; 10(12):1808-1825. PMC: 7710563. DOI: 10.1158/2159-8290.CD-20-0522. View

3.
Wu F, Zhang W, Shao H, Bo H, Shen H, Li J . Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy. Cancer Lett. 2013; 339(2):195-207. DOI: 10.1016/j.canlet.2013.06.009. View

4.
Liu Z, Liu L, Weng S, Guo C, Dang Q, Xu H . Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer. Nat Commun. 2022; 13(1):816. PMC: 8831564. DOI: 10.1038/s41467-022-28421-6. View

5.
Gu C, Cai J, Xu Z, Zhou S, Ye L, Yan Q . MiR-532-3p suppresses colorectal cancer progression by disrupting the ETS1/TGM2 axis-mediated Wnt/β-catenin signaling. Cell Death Dis. 2019; 10(10):739. PMC: 6768886. DOI: 10.1038/s41419-019-1962-x. View